N-6404 Neratinib, Free Base, >99%

Synonyms : [HKI-272]

Related Terms : [Nerlynx]

  • Size
  • US $
  • £
  • ¥
  • 100 mg
  • 119
  • 109
  • 93
  • 18,500
  • Add to Cart
  • Out of stock
  • 200 mg
  • 184
  • 169
  • 144
  • 28,600
  • Add to Cart
  • Out of stock
  • 500 mg
  • 263
  • 241
  • 206
  • 40,900
  • Add to Cart
  • Out of stock
  • 1 g
  • 390
  • 358
  • 306
  • 60,700
  • Add to Cart
  • Out of stock
  • 2 g
  • 594
  • 546
  • 467
  • 92,500
  • Add to Cart
  • Out of stock
  • 5 g
  • 1,125
  • 1,035
  • 885
  • 175,100
  • Add to Cart
  • Out of stock
  • 10 g
  • 1,670
  • 1,536
  • 1,314
  • 260,000
  • Add to Cart
  • Out of stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Free Shipping and Handling to the U.S. and 32 Other Countries
  • M.W. 557.04
  • C30H29ClN6O3
  • [698387-09-6]

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 2 mg/mL with warming; very poorly soluble in ethanol; very poorly soluble in water; maximum solubility in plain water is estimated to be about 5-20 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.

Select Lot Number to view Certificate of Analysis

View the SDS for this product

  • July 27, 2023:  we expect our next  lot of  N-6404 Neratnib, Free Base to be ready to ship during the week of August 21, 2023 or sooner.
  • Neratinib, also known as HKI-272, is considered to be a second-generation inhibitor of the ErbB family of receptor kinases. Sequist, L.V., et al. "Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer." Oncologist 12: 325-330 (2007).
  • Neratinib is an irreversible inhibitor of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER-2) tyrosine kinases by targeting a cysteine residue in the ATP-binding site of the receptor. Rabindran, S.K., et al. "Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase." Cancer Res. 64: 3958-3965 (2004).
  • Neratinib inhibits the proliferation of HER-2 overexpressing human breast cancer cell lines and EGFR-dependent cells in vitro. In vivo, neratinib is active against HER-2- and EGFR-dependent tumor xenograft models. Rabindran, S.K., et al. "Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase." Cancer Res. 64: 3958-3965 (2004).
  • Acquired resistance of non-small cell lung cancers to gefitinib because of a T790M mutation in the EGFR kinase domain is circumvented by neratinib. Kwak, E.L., et al. "Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib." Proc. Natl. Acad. Sci. USA 102: 7665-7670 (2005).
  • Neratinib is active against HER-2-positive breast cancer in patients. Wong, K.K., et al. "HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: Preliminary phase 1 results in patients with solid tumors." J. Clin. Oncol. 24: 3018 (2006).
  • Another CAS number previously assigned to neratinib, namely 736156-77-7, has been deleted by CAS and is no longer in use.
  • Neratinib (as the maleate salt) is the active ingredient in the drug sold under the trade name Nerlynx®. This drug is currently approved in at least one country for the extended adjuvant treatment of adult patients with early stage HER-2-overexpressed/ampified brest cancer, to follow adjuvant trastuzumab-based therapy. NOTE: THE NERATINIB SOLD BY LC LABORATORIES FOR RESEARCH IS NOT NERLYNX®, AND IS NOT FOR HUMAN USE.
  • Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.